125 related articles for article (PubMed ID: 37876297)
1. Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach.
Le K; Vollenweider J; Han J; Staudinger N; Stenson M; Bayraktar L; Wellik LE; Maurer MJ; McPhail ED; Witzig TE; Gupta M
Hematol Oncol; 2024 Jan; 42(1):e3233. PubMed ID: 37876297
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.
Han JJ; O'byrne M; Stenson MJ; Maurer MJ; Wellik LE; Feldman AL; McPhail ED; Witzig TE; Gupta M
Blood Cancer J; 2018 Nov; 8(11):110. PubMed ID: 30420593
[TBL] [Abstract][Full Text] [Related]
3. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Lin Q; Atwell C; Medeiros LJ; Amin HM
Hum Pathol; 2005 Sep; 36(9):939-44. PubMed ID: 16153455
[TBL] [Abstract][Full Text] [Related]
4. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA
Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336
[TBL] [Abstract][Full Text] [Related]
6. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.
Amin HM; Medeiros LJ; Ma Y; Feretzaki M; Das P; Leventaki V; Rassidakis GZ; O'Connor SL; McDonnell TJ; Lai R
Oncogene; 2003 Aug; 22(35):5399-407. PubMed ID: 12934099
[TBL] [Abstract][Full Text] [Related]
8. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
[TBL] [Abstract][Full Text] [Related]
9. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
Lin Q; Lai R; Chirieac LR; Li C; Thomazy VA; Grammatikakis I; Rassidakis GZ; Zhang W; Fujio Y; Kunisada K; Hamilton SR; Amin HM
Am J Pathol; 2005 Oct; 167(4):969-80. PubMed ID: 16192633
[TBL] [Abstract][Full Text] [Related]
11. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.
Cho-Vega JH; Rassidakis GZ; Amin HM; Tsioli P; Spurgers K; Remache YK; Vega F; Goy AH; Gilles F; Medeiros LJ
Leukemia; 2004 Nov; 18(11):1872-8. PubMed ID: 15385932
[TBL] [Abstract][Full Text] [Related]
12.
Andersson EI; Brück O; Braun T; Mannisto S; Saikko L; Lagström S; Ellonen P; Leppä S; Herling M; Kovanen PE; Mustjoki S
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32188095
[TBL] [Abstract][Full Text] [Related]
13. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
[TBL] [Abstract][Full Text] [Related]
14. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
15. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.
Kim BH; Min YS; Choi JS; Baeg GH; Kim YS; Shin JW; Kim TY; Ye SK
Exp Mol Med; 2011 May; 43(5):313-21. PubMed ID: 21499010
[TBL] [Abstract][Full Text] [Related]
16. Activation status of the JAK/STAT3 pathway in mantle cell lymphoma.
Yared MA; Khoury JD; Medeiros LJ; Rassidakis GZ; Lai R
Arch Pathol Lab Med; 2005 Aug; 129(8):990-6. PubMed ID: 16048411
[TBL] [Abstract][Full Text] [Related]
17. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.
Qiu L; Lai R; Lin Q; Lau E; Thomazy DM; Calame D; Ford RJ; Kwak LW; Kirken RA; Amin HM
Blood; 2006 Oct; 108(7):2407-15. PubMed ID: 16763206
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.
de Pádua Covas Lage LA; Brito CV; Levy D; Culler HF; Freitas Couto SC; de Oliveira LBA; Nogueira Zerbini MC; Rocha V; Pereira J
Leuk Res; 2022 Mar; 114():106794. PubMed ID: 35131666
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
